Plain-English translation of NCT02021604 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tests , a specialized imaging scan combined with a CT scan, to help doctors find exactly where problems are occurring in the pancreas of children with congenital hyperinsulinism or insulinoma. The scan uses a radioactive tracer that lights up pancreatic cells, making it easier for surgeons to plan surgery precisely. This approach has already been used safely in over 200 patients worldwide and is considered the best way to prepare for pancreatic surgery in children who need it.
Children with congenital hyperinsulinism produce too much insulin, which causes dangerously low blood sugar that can harm the brain. When medicines don't work, surgery is the only option—but doctors need to know exactly where the problem is in the pancreas. Current methods to find these problem areas are invasive and risky; this medication offers a safer, more accurate way to guide surgeons.
You likely qualify if…
You likely don't qualify if…
You would receive the tracer injection and then undergo a specialized PET scan combined with a CT scan of your pancreas. The scan takes a few hours and is painless—you lie still while the imaging equipment takes detailed three-dimensional pictures of your pancreas. If you are nursing, you would need to stop breastfeeding for 48 hours after the injection. The images help your surgical team plan the safest and most effective operation.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States